Insulet Corp PODD
We take great care to ensure that the data presented and summarized in this overview for INSULET CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PODD
View all-
Vanguard Group Inc Valley Forge, PA8.67MShares$2.6 Billion0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.08MShares$1.82 Billion0.36% of portfolio
-
Black Rock Inc. New York, NY6.06MShares$1.82 Billion0.03% of portfolio
-
State Street Corp Boston, MA3.02MShares$907 Million0.03% of portfolio
-
Baillie Gifford & CO2.25MShares$675 Million0.53% of portfolio
-
Geode Capital Management, LLC Boston, MA1.87MShares$561 Million0.04% of portfolio
-
Clearbridge Investments, LLC New York, NY1.48MShares$444 Million0.35% of portfolio
-
Invesco Ltd. Atlanta, GA1.41MShares$423 Million0.07% of portfolio
-
Fil LTD Hamilton, D01.29MShares$386 Million0.35% of portfolio
-
Morgan Stanley New York, NY1.21MShares$362 Million0.02% of portfolio
Latest Institutional Activity in PODD
Top Purchases
Top Sells
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Insider Transactions at PODD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 13
2025
|
Dan Manea SVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
1,300
-12.51%
|
$390,000
$300.05 P/Share
|
|
Jun 13
2025
|
Prem Singh SVP, Global Operations |
SELL
Open market or private sale
|
Direct |
2,327
-35.97%
|
$698,100
$300.05 P/Share
|
|
Jun 13
2025
|
Prem Singh SVP, Global Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
1,257
+16.27%
|
$208,662
$166.62 P/Share
|
|
Jun 09
2025
|
Luciana Borio Director |
SELL
Open market or private sale
|
Direct |
481
-13.48%
|
$146,705
$305.73 P/Share
|
|
May 22
2025
|
Elizabeth H Weatherman Director |
BUY
Grant, award, or other acquisition
|
Direct |
778
+12.92%
|
-
|
|
May 22
2025
|
Flavia Pease Director |
BUY
Grant, award, or other acquisition
|
Direct |
778
+17.65%
|
-
|
|
May 22
2025
|
Timothy J Scannell Director |
BUY
Grant, award, or other acquisition
|
Direct |
778
+2.42%
|
-
|
|
May 22
2025
|
Timothy C. Stonesifer Director |
BUY
Grant, award, or other acquisition
|
Direct |
778
+17.65%
|
-
|
|
May 22
2025
|
Wayne A.I. Frederick Director |
BUY
Grant, award, or other acquisition
|
Direct |
778
+16.25%
|
-
|
|
May 22
2025
|
Jessica Hopfield Director |
BUY
Grant, award, or other acquisition
|
Direct |
778
+2.73%
|
-
|
|
May 22
2025
|
Michael R Minogue Director |
BUY
Grant, award, or other acquisition
|
Direct |
778
+26.5%
|
-
|
|
May 22
2025
|
Luciana Borio Director |
BUY
Grant, award, or other acquisition
|
Direct |
778
+17.9%
|
-
|
|
May 14
2025
|
John W. Kapples SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
5,278
-18.55%
|
$1,678,404
$318.47 P/Share
|
|
May 14
2025
|
John W. Kapples SVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,278
+15.65%
|
$501,410
$95.43 P/Share
|
|
May 13
2025
|
Ashley Mc Evoy President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
9,540
+50.0%
|
-
|
|
May 13
2025
|
Jessica Hopfield Director |
SELL
Open market or private sale
|
Direct |
5,235
-16.28%
|
$1,659,495
$317.54 P/Share
|
|
May 13
2025
|
Jessica Hopfield Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,235
+14.0%
|
$146,580
$28.87 P/Share
|
|
May 13
2025
|
Eric Benjamin EVP, CPXO |
SELL
Open market or private sale
|
Direct |
3,001
-12.55%
|
$960,320
$320.0 P/Share
|
|
May 13
2025
|
Eric Benjamin EVP, CPXO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,001
+11.15%
|
$276,092
$92.11 P/Share
|
|
May 01
2025
|
Ana Maria Chadwick EVP, CFO & Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,765
-11.01%
|
$441,250
$250.25 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 90.9K shares |
|---|---|
| Exercise of conversion of derivative security | 32.6K shares |
| Open market or private purchase | 100 shares |
| Open market or private sale | 56.4K shares |
|---|---|
| Payment of exercise price or tax liability | 37K shares |